CAPTRUST Financial Advisors
OTLK icon

CAPTRUST Financial Advisors’s Outlook Therapeutics OTLK Stock Holding History

CAPTRUST Financial Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,807
Closed -$30K – 2501
2023
Q4 		$30K Sell
3,807
-3,000
-44% -$25.4K ﹤0.01% 2611
2023
Q3 		$30.1K Buy
6,807
+5,779
+562% +$128K ﹤0.01% 2509
2023
Q2 		$35.8K Buy
1,028
+500
+95% +$13.6K ﹤0.01% 2445
2023
Q1 		$11.5K Buy
+528
New +$11.8K ﹤0.01% 2267
2022
Q4 		– Sell
-500
Closed -$12K – 2151
2022
Q3 		$12K Hold
500
– – ﹤0.01% 2027
2022
Q2 		$10K Hold
500
– – ﹤0.01% 3751
2022
Q1 		$18K Buy
+500
New +$15.6K ﹤0.01% 3457

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

CAPTRUST Financial Advisors's OTLK Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 3,807 shares — an estimated $30K sold.

CAPTRUST Financial Advisors first reported a position in OTLK in Q1 2022 and held it in 7 quarters. The position peaked at $35.8K in Q2 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 3,807 Outlook Therapeutics shares in Q1 2024, an estimated $30K.
  • CAPTRUST Financial Advisors first reported a position in Outlook Therapeutics in Q1 2022 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Outlook Therapeutics position peaked at $35.8K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.